

RealRate

PHARMACEUTICAL 2019

LUMOS PHARMA INC. Rank 48 of 363









RealRate

PHARMACEUTICAL 2019

LUMOS PHARMA INC. Rank 48 of 363



The relative strengths and weaknesses of LUMOS PHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LUMOS PHARMA INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of LUMOS PHARMA INC. is the variable Research and Development, reducing the Economic Capital Ratio by 9.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 234%, being 197% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	127,072
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,847
Liabilities, Non-Current	6,949
Other Assets	49,940
Other Compr. Net Income	0
Other Expenses	-6,968
Other Liabilities	0
Other Net Income	1,875
Other Revenues	12,500
Property and Equipment	3,727
Research and Development	45,694
Selling, General and Administrative Expense	29,218

Output Variable	Value in 1000 USD
Assets	180,739
Liabilities	15,796
Expenses	67,944
Revenues	12,500
Stockholders Equity	164,943
Net Income	-53,569
Comprehensive Net Income	-53,569
Economic Capital Ratio	234%

